GENE ONLINE|News &
Opinion
Blog

2023-03-01| ChinaSpecial

Investigate the Current Status of Rivaroxaban Generic Drug Application in China

by CHINGCHENG-LAW
Share To
Cardiovascular disease has become a serious public health problem with the increasing degree of aging in China. Anticoagulants are essential to prevent thrombosis and reduce the risk of stroke. Rivaroxaban has occupied a certain share of the Chinese market as an oral anticoagulant.

Rivaroxaban is an oral anticoagulant and an oral anticoagulant drug that directly inhibits thrombin. It is often used to prevent thrombosis and reduce the risk of stroke. It can prevent the generation of thrombin in the blood, thereby reducing the formation of thrombus and reducing the risk of thrombosis-related diseases. Rivaroxaban is commonly used to treat conditions such as venous thrombosis, pulmonary embolism, atrial fibrillation, and artificial heart valve replacement surgery.

It's free! Log in now to read

LATEST
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
EVENT
Scroll to Top